Penumbra (PEN) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed Solventum (SOLV) over the past year, gaining 27.0% versus a gain of 19.0%. Solventum is the larger company by market cap ($14.62 billion vs $12.46 billion), about 1.2 times the size, while Penumbra is growing revenue faster (+17.5% vs +0.9%). On valuation, Solventum trades at a lower forward P/E (11.9x vs 51.6x for Penumbra).
Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | SOLV |
|---|---|---|
| Share price | $316.35 | $85.91 |
| Market cap | $12.46B | $14.62B |
| 1-day change | -0.22% | +0.04% |
| YTD return | +1.75% | +8.38% |
| 1-year return | +27.03% | +19.01% |
| 5-year return | +18.15% | — |
| P/E ratio (TTM) | 77.73 | 10.51 |
| Forward P/E | 51.59 | 11.88 |
| EPS (TTM) | $4.07 | $8.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $8.32B |
| Revenue growth (YoY) | +17.50% | +0.86% |
| Net income (latest FY) | $177.69M | $1.56B |
| Gross margin | 67.14% | 53.47% |
| Operating margin | 13.48% | 26.20% |
| Net margin | 12.66% | 18.69% |
| 52-week high | $362.41 | $94.16 |
| 52-week low | $221.26 | $62.38 |
| Distance from 52-week high | -12.71% | -8.77% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +14.30% | +9.78% |
| Average volume | 344.71K | 1.02M |
| Shares outstanding | 39.39M | 170.22M |
| Employees | 4,700 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra trades at a higher earnings multiple (77.7x vs 10.5x trailing P/E).
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 12.7 cents for Penumbra.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +0.86%).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
PEN vs SOLV FAQ
Which is bigger, Penumbra or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.62B compared with $12.46B for Penumbra (PEN).
Which stock has performed better over the past year, PEN or SOLV?
PEN returned +27.03% over the past 12 months, compared with +19.01% for SOLV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or SOLV?
SOLV has the lower trailing P/E at 10.5, versus 77.7 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Penumbra and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.